Breaking News

Evotec, Haplogen in Infectious Disease Pact

November 15, 2012

Will co-develop drugs against viruses

Evotec and Haplogen have signed a collaboration agreement to discover and develop small molecules against viral infectious diseases. Financial terms were not disclosed.
 
The companies will co-develop drugs against a human protein that is essential for pathogenic viruses to infect their host cell. This protein was discovered by Haplogen’s technology that identifies host factors for infectious pathogens. Evotec will further develop lead compounds and apply its drug discovery platform to find additional small molecule inhibitors.
 
“This partnership will ensure that our therapeutic program advances with increasing pace to discover molecules for clinical testing in those patients that are at high risk of virus infections,” said Georg Casari, chief executive officer of Haplogen. “We are excited that Evotec shares our vision and has joined forces on this first-in-class drug target.”
 
Mario Polywka, chief operating officer of Evotec, said, “Part of Evotec’s strategy is to pursue innovative, early stage projects and develop them to a partnering position before the clinic. We are delighted to partner with Haplogen to optimize their protein inhibitors. Haplogen’s powerful target discovery technology is an excellent complement to Evotec’s small molecule discovery and development capabilities. We hope that this is the start of a long-term relationship.”
 

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016